Citations (52)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Robin Epplen, Michael Stöckle, Udo Engelmann, Axel Heidenreich & Carsten-Henning Ohlmann. (2011) Differential effects of ibandronate, docetaxel and farnesol treatment alone and in combination on the growth of prostate cancer cell lines. Acta Oncologica 50:1, pages 127-133.
Read now
Read now
Michele Caraglia, Monica Marra, Silvio Naviglio, Gerardo Botti, Raffaele Addeo & Alberto Abbruzzese. (2010) Zoledronic acid: an unending tale for an antiresorptive agent. Expert Opinion on Pharmacotherapy 11:1, pages 141-154.
Read now
Read now
Anders Ullén, Stephan Schwarz, Lena Lennartsson, Karl-Mikael Kälkner, Per Sandström, Fernanda Costa, Bo Lennernäs, Stig Linder & Sten Nilsson. (2009) Zoledronic acid induces caspase-dependent apoptosis in renal cancer cell lines. Scandinavian Journal of Urology and Nephrology 43:2, pages 98-103.
Read now
Read now
Claire Morgan, Paul D. Lewis, Rachel M. Jones, Gianfilippo Bertelli, Gerry A. Thomas & Robert C. F. Leonard. (2007) The in vitro anti-tumour activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer. Acta Oncologica 46:5, pages 669-677.
Read now
Read now
Cai Grau, Morten Høyer, Jacob Lindegaard & Jens Overgaard. (2006) The emerging evidence for Stereotactic Body Radiotherapy. Acta Oncologica 45:7, pages 771-774.
Read now
Read now
A. Ugur Ural & Ferit Avcu. (2006) Additive/synergistic anti-tumoral effects of the combination of docetaxel and zoledronic acid on prostate cancer cells: Possible mechanisms?. Acta Oncologica 45:4, pages 491-492.
Read now
Read now
Seymour Levitt. (2005) Second Acta Oncologia Symposium on Prostate Cancer Controversies. Acta Oncologica 44:6, pages 526-528.
Read now
Read now
Articles from other publishers (45)
Rafieh Bagherifar, Seyed Hossein Kiaie, Zahra Hatami, Armin Ahmadi, Abdolvahid Sadeghnejad, Behzad Baradaran, Reza Jafari & Yousef Javadzadeh. (2021) Nanoparticle-mediated synergistic chemoimmunotherapy for tailoring cancer therapy: recent advances and perspectives. Journal of Nanobiotechnology 19:1.
Crossref
Crossref
Congcong Wu, Hua Jiang & Jianghua Chen. (2020) A Systematic Review and Meta-Analysis about the Effect of Bisphosphonates on the Risk of Skeletal-Related Event in Men with Prostate Cancer. Anti-Cancer Agents in Medicinal Chemistry 20:13, pages 1604-1612.
Crossref
Crossref
Anna Nasulewicz‐Goldeman, Waldemar Goldeman, Ewa Mrówczyńska & Joanna Wietrzyk. (2019) Biological effects of aromatic bis[aminomethylidenebis(phosphonic)] acids in osteoclast precursors in vitro. Chemical Biology & Drug Design 94:4, pages 1835-1848.
Crossref
Crossref
Parthasarathy Seshacharyulu, Satyanarayana Rachagani, Sakthivel Muniyan, Jawed A. Siddiqui, Eric Cruz, Sunandini Sharma, Ramakrishnan Krishnan, Brigham J. Killips, Yuri Sheinin, Subodh M. Lele, Lynette M. Smith, Geoffrey A. Talmon, Moorthy P. Ponnusamy, Kaustubh Datta & Surinder K. Batra. (2019) FDPS cooperates with PTEN loss to promote prostate cancer progression through modulation of small GTPases/AKT axis. Oncogene 38:26, pages 5265-5280.
Crossref
Crossref
Congcong Wu, Wenjun Chen, Jian Wu, Xi Zhang, Xuanzhang Huang, Ruifang Lin, Baoling Zhu & Hua Jiang. (2019) Effect of bisphosphonates on overall survival in subgroups of patients with prostate cancer. Clinical & Experimental Metastasis 36:3, pages 199-209.
Crossref
Crossref
Lidia Śliwka, Katarzyna Wiktorska, Piotr Suchocki, Małgorzata Milczarek, Szymon Mielczarek, Katarzyna Lubelska, Tomasz Cierpiał, Piotr Łyżwa, Piotr Kiełbasiński, Anna Jaromin, Anna Flis & Zdzisław Chilmonczyk. (2016) The Comparison of MTT and CVS Assays for the Assessment of Anticancer Agent Interactions. PLOS ONE 11:5, pages e0155772.
Crossref
Crossref
Mahitab Elsayed, Daisuke Kobayashi, Toshio Kubota, Naoya Matsunaga, Ryusei Murata, Yuko Yoshizawa, Natsuki Watanabe, Tohru Matsuura, Yuya Tsurudome, Takashi Ogino, Shigehiro Ohdo & Takao Shimazoe. (2016) Synergistic Antiproliferative Effects of Zoledronic Acid and Fluvastatin on Human Pancreatic Cancer Cell Lines: An <i>in Vitro</i> Study. Biological & Pharmaceutical Bulletin Biological and Pharmaceutical Bulletin 39:8, pages 1238-1246.
Crossref
Crossref
Umut Varol, Mustafa Degirmenci, Burcak Karaca, Harika Atmaca, Asli Kisim, Selim Uzunoglu, Canfeza Sezgin, Ulus Ali Sanli & Ruchan Uslu. (2014) Zoledronic acid increases cytotoxicity by inducing apoptosis in hormone and docetaxel-resistant prostate cancer cell lines. Tumor Biology 36:2, pages 779-786.
Crossref
Crossref
Yue Pan, Haiyong Jin, Wei Chen, Zhixian Yu, Tingyu Ye, Yuancai Zheng, Zhiliang Weng & Feng Wang. (2014) Docetaxel with or without zoledronic acid for castration-resistant prostate cancer. International Urology and Nephrology 46:12, pages 2319-2326.
Crossref
Crossref
Alexandre Chamouni & Franck Oury. (2014) Reciprocal interaction between bone and gonads. Archives of Biochemistry and Biophysics 561, pages 147-153.
Crossref
Crossref
Jamal Zekri, Maged Mansour & Syed Mustafa Karim. (2014) The anti-tumour effects of zoledronic acid. Journal of Bone Oncology 3:1, pages 25-35.
Crossref
Crossref
F. Gomez-Veiga, J. Ponce-Reixa, S. Martinez-Breijo, J. Planas & J. Morote. (2013) Advances in prevention and treatment of bone metastases in prostate cancer. Role of RANK/RANKL inhibition. Actas Urológicas Españolas (English Edition) 37:5, pages 292-304.
Crossref
Crossref
F. Gomez-Veiga, J. Ponce-Reixa, S. Martinez-Breijo, J. Planas & J. Morote. (2013) Avances en la prevención y el tratamiento de las metástasis óseas en cáncer de próstata. Papel de la inhibición de RANK/RANKL. Actas Urológicas Españolas 37:5, pages 292-304.
Crossref
Crossref
Giuseppe De Rosa, Gabriella Misso, Giuseppina Salzano & Michele Caraglia. (2013) Bisphosphonates and Cancer: What Opportunities from Nanotechnology?. Journal of Drug Delivery 2013, pages 1-17.
Crossref
Crossref
Shanna Rajpar & Karim Fizazi. (2013) Bone Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer. The Cancer Journal 19:1, pages 66-70.
Crossref
Crossref
H.J. Meulenbeld, E.D. van Werkhoven, J.L.L.M. Coenen, G.J. Creemers, O.J.L. Loosveld, P.C. de Jong, A.J. ten Tije, S.D. Fosså, M. Polee, W. Gerritsen, O. Dalesio & R. de Wit. (2012) Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro). European Journal of Cancer 48:16, pages 2993-3000.
Crossref
Crossref
Kate McKeage. (2012) Docetaxel. Drugs 72:11, pages 1559-1577.
Crossref
Crossref
H K Koul, S Koul & R B Meacham. (2011) New role for an established drug? Bisphosphonates as potential anticancer agents. Prostate Cancer and Prostatic Diseases 15:2, pages 111-119.
Crossref
Crossref
Y. Loriot, C. Massard & K. Fizazi. (2012) Recent developments in treatments targeting castration-resistant prostate cancer bone metastases. Annals of Oncology 23:5, pages 1085-1094.
Crossref
Crossref
Maria Michailidou & Ingunn Holen. 2012. Prevention of Bone Metastases. Prevention of Bone Metastases
145
169
.
T. Todenhöfer, C. Schwentner, D. Schilling, G. Gakis & A. Stenzl. (2011) Behandlung von ossären Metastasen und therapieinduzierter Osteoporose beim ProstatakarzinomTreatment of metastatic bone disease and treatment-induced osteoporosis in prostate cancer. Der Urologe 50:9, pages 1055-1063.
Crossref
Crossref
Kun‐Yun Yeh, John W.‐C. Chang, Ying‐Ying Li, Cheng‐Hsu Wang & Hung‐Ming Wang. (2010) Tumor growth inhibition of metastatic nasopharyngeal carcinoma cell lines by low dose of arsenic trioxide via alteration of cell cycle progression and induction of apoptosis. Head & Neck 33:5, pages 734-742.
Crossref
Crossref
Sarah A. Holstein & Raymond J. Hohl. 2011. Protein Prenylation Part B. Protein Prenylation Part B
301
319
.
Reshma Mahtani & Mohammad Jahanzeb. (2010) Bisphosphonates as Anticancer Therapy for Early Breast Cancer. Clinical Breast Cancer 10:5, pages 359-366.
Crossref
Crossref
Takashi Kobayashi, Yosuke Shimizu, Naoki Terada, Toshinari Yamasaki, Eijiro Nakamura, Yoshinobu Toda, Hiroyuki Nishiyama, Toshiyuki Kamoto, Osamu Ogawa & Takahiro Inoue. (2010) Regulation of androgen receptor transactivity and mTOR–S6 kinase pathway by Rheb in prostate cancer cell proliferation. The Prostate 70:8, pages 866-874.
Crossref
Crossref
Rhys D. Clyburn, Penny Reid, Catherine A. Evans, Diane V. Lefley & Ingunn Holen. (2009) Increased anti-tumour effects of doxorubicin and zoledronic acid in prostate cancer cells in vitro: supporting the benefits of combination therapy. Cancer Chemotherapy and Pharmacology 65:5, pages 969-978.
Crossref
Crossref
Kishan J. Pandya, Ajeet Gajra, Ghulam M. Warsi, Eliza Argonza-Aviles, Solveig G. Ericson & Antoinette J. Wozniak. (2010) Multicenter, randomized, phase 2 study of zoledronic acid in combination with docetaxel and carboplatin in patients with unresectable stage IIIB or stage IV non-small cell lung cancer. Lung Cancer 67:3, pages 330-338.
Crossref
Crossref
Robert Segal, Fadi Brimo & Wassim Kassouf. (2010) Normalization of Prostate-Specific Antigen and Reduction of Clinical Metastasis Following Zoledronic Acid Treatment in Castrate-Resistant Prostate Cancer. UroToday International Journal 03:01.
Crossref
Crossref
Monica Marra, Daniele Santini, Giuseppina Meo, Bruno Vincenzi, Silvia Zappavigna, Alfonso Baldi, Maciej Rosolowski, Giuseppe Tonini, Markus Loeffler, Ruth Lupu, Santolo Rosario Addeo, Alberto Abbruzzese, Alfredo Budillon & Michele Caraglia. (2009) Cyr61 downmodulation potentiates the anticancer effects of zoledronic acid in androgen‐independent prostate cancer cells. International Journal of Cancer 125:9, pages 2004-2013.
Crossref
Crossref
Rishi Nayyar, Nitin Sharma & Narmada P Gupta. (2009) Docetaxel-based chemotherapy with zoledronic acid and prednisone in hormone refractory prostate cancer: Factors predicting response and survival. International Journal of Urology 16:9, pages 726-731.
Crossref
Crossref
Jonathan Shamash. (2009) Future directions in non-endocrine systemic treatment of metastatic prostate cancer. Surgical Oncology 18:3, pages 283-288.
Crossref
Crossref
Luis Costa & Pierre P Major. (2009) Effect of bisphosphonates on pain and quality of life in patients with bone metastases. Nature Reviews Clinical Oncology 6:3, pages 163-174.
Crossref
Crossref
Kavitha Ramachandran, Gopal Gopisetty, Edna Gordian, Loida Navarro, Christiane Hader, Isildinha M. Reis, Wolfgang A. Schulz & Rakesh Singal. (2009)
Methylation-Mediated Repression of
GADD45α
in Prostate Cancer and Its Role as a Potential Therapeutic Target
. Cancer Research 69:4, pages 1527-1535.
Crossref
Crossref
Sarah A. Holstein & Raymond J. Hohl. 2009. Pharmacology and Therapeutics. Pharmacology and Therapeutics
951
957
.
Francesco Fabbri, Giovanni Brigliadori, Silvia Carloni, Paola Ulivi, Ivan Vannini, Anna Tesei, Rosella Silvestrini, Dino Amadori & Wainer Zoli. (2008) Zoledronic acid increases docetaxel cytotoxicity through pMEK and Mcl-1 inhibition in a hormone-sensitive prostate carcinoma cell line. Journal of Translational Medicine 6:1.
Crossref
Crossref
M. Marra, D. Santini, G. Tonini, G. Meo, S. Zappavigna, G. Facchini, A. Morabito, A. Abbruzzese, G. Cartenì, A. Budillon & M. Caraglia. (2008) Molecular and preclinical models enhancing anti-tumour activity of zoledronic acid. European Journal of Cancer Supplements 6:14, pages 79-85.
Crossref
Crossref
Layka A. Asbagh, Selim Uzunoglu & Cag Cal. (2008) Zoledronic acid effects interleukin-6 expression in hormone-independent prostate cancer cell lines. International braz j urol 34:3, pages 355-364.
Crossref
Crossref
Fred Saad. (2008) New research findings on zoledronic acid: Survival, pain, and anti-tumour effects. Cancer Treatment Reviews 34:2, pages 183-192.
Crossref
Crossref
Ying-Ying Li, John W.-C. Chang, Wen-Chi Chou, Chuang-Chi Liaw, Hung-Ming Wang, Jen-Seng Huang, Cheng-Hsu Wang & Kun-Yun Yeh. (2008) Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers. Lung Cancer 59:2, pages 180-191.
Crossref
Crossref
Verena Stresing, Florence Daubiné, Ismahène Benzaid, Hannu Mönkkönen & Philippe Clézardin. (2007) Bisphosphonates in cancer therapy. Cancer Letters 257:1, pages 16-35.
Crossref
Crossref
Giuseppe Di Lorenzo, Riccardo Autorino, Sisto Perdonà, Michele De Laurentiis, Massimo D'Armiento, Giuseppe Cancello, Vincenzo Mirone, Ciro Imbimbo, Nicola Longo, Vincenzo Altieri, Gianpaolo Tortora, William D. Figg & Sabino De Placido. (2007) Docetaxel, Vinorelbine, and Zoledronic Acid as First-Line Treatment in Patients with Hormone Refractory Prostate Cancer: A Phase II Study. European Urology 52:4, pages 1020-1027.
Crossref
Crossref
Stephen R. Mattarollo, Tony Kenna, Mie Nieda & Andrew J. Nicol. (2007) Chemotherapy and zoledronate sensitize solid tumour cells to Vγ9Vδ2 T cell cytotoxicity. Cancer Immunology, Immunotherapy 56:8, pages 1285-1297.
Crossref
Crossref
Panagiotis A. Konstantinopoulos, Michalis V. Karamouzis & Athanasios G. Papavassiliou. (2007) Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nature Reviews Drug Discovery 6:7, pages 541-555.
Crossref
Crossref
Noel W. Clarke. (2006) New Research Findings on Clinical Benefits of Bisphosphonates in Patients With Advanced Prostate Cancer. European Urology Supplements 5:17, pages 880-885.
Crossref
Crossref
Fred Saad. (2006) The Treatment Continuum in the Management of Prostate Cancer Patients: What's New?. European Urology Supplements 5:7, pages 539-542.
Crossref
Crossref